Oxytocin treatment attenuates amygdala activity in autism: a treatment-mechanism study with long-term follow-up

摘要

MRI scanning was performed at baseline (T0); after a single dose of oxytocin or placebo treatment (SD); after the 4-week (oxytocin/placebo) treatment (T1); and at two follow-up sessions, 4 weeks (T2) and one year after cessation of the treatment (T3). One participant of the oxytocin group was excluded from the analyses, due to self-termination of participation (unrelated to the treatment). One participant of the placebo group was excluded from the MRI analyses due to excessive in-scanner head motion (mean frame-wise displacement exceeding > 0.5 mm). Six additional participants (three oxytocin, three placebo) were lost for follow-up session T3.